Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14473669 | 0.75 | ALDH1A1 (0.37) | CA2ALDH1A1TSHR | |
| SCHEMBL14455044 | 0.72 | GABRA1 (0.39) | CA2GABRA1GABRB2TSHR | |
| SCHEMBL17123122 | 0.71 | CA2 (0.35) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL12804798 | 0.71 | BCL2L1 (0.45) | CA2ALDH1A1TSHRTDP1 | |
| SCHEMBL22904342 | 0.71 | CD44 (0.40) | ALDH1A1TSHRTDP1 | |
| SCHEMBL31284979 | 0.71 | TRPA1 (0.34) | — | |
| SCHEMBL22904340 | 0.70 | MAPT (0.31) | ALDH1A1TDP1 | |
| SCHEMBL24446032 | 0.70 | GABRA1 (0.38) | GABRA1GABRB2 | |
| SCHEMBL24871632 | 0.70 | CA2 (0.44) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL22904316 | 0.69 | PNMT (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198261-A1 | AURORA KINASE INHIBITORS AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198261-A1 | AURORA KINASE INHIBITORS AND USES THEREOF | AURKA, AURKC, AURKB | CA2 1727/4885GABRA1 4564/4885GABRB2 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.